Risk factors

IDEAYA Biosciences relies entirely on unapproved precision medicine and synthetic lethality product candidates in clinical development. The company depends heavily on third-party manufacturers, suppliers, and diagnostic developers for its clinical trials. Substantial additional financing will be required to fund ongoing research, trials, and potential commercialization.

Independence Realty Trust depends heavily on multifamily apartment investments concentrated in the Southeastern United States. Short-term resident leases and local economic downturns directly threaten operational profitability and distributions. Reliance on external capital, mortgage debt, and government-backed lenders like Fannie Mae and Freddie Mac exposes the company to financing risks.

Portfolio heavily comprises office assets experiencing lower demand from work-from-home trends. Assets are geographically concentrated in the Washington D.C. area, especially National Landing. Operations and tenants depend heavily on federal government spending and the GSA.

Aging inland waterway infrastructure threatens KMT operations and costs. Oil and gas extraction regulations could negatively impact KDS. Weather conditions and climate change impacts disrupt facilities and transportation. Reliance on acquisitions and key customers poses growth and revenue risks.

Telecom competition, fast technology shifts and heavy network investment dominate Liberty Global’s operating risks.

Medifast faces intense competition from weight-loss medicines and shifting consumer preference toward integrated lifestyle approaches.

MGM carries $6.4 billion of consolidated debt and $1.8 billion in annual rent, limiting cash available for operations and growth.

Neogenomics faces intense competition in genetic and molecular testing from established laboratories like Quest and LabCorp.

Goodwill and intangible assets total $3.8 billion, representing 57% of total assets.

Occidental Petroleum's risk section is dominated by commodity price volatility, high debt from the CrownRock acquisition, and stringent environmental and climate regulations.

Penumbra faces intense medical device competition, reliance on key product families, pricing pressures from GPOs, and stringent FDA and foreign regulations.

Polaris faces economic sensitivity affecting consumer discretionary spending on powersports and marine products.